Semaglutide Alters Gastric Electrical Activity in Overweight and Obese Patients
Background
The GLP-1 receptor agonist Semaglutide is a highly effective treatment for type 2 diabetes and obesity, primarily by enhancing insulin secretion, suppressing glucagon, and delaying gastric emptying. While delayed gastric emptying is a well-known mechanism contributing to satiety and weight loss, the specific impact of Semaglutide on the underlying gastric electrical activity that orchestrates gut motility has been less understood.
Results
After 16 weeks of Semaglutide treatment, significant changes in gastric electrical activity were observed. The dominant gastric slow wave frequency decreased by an average of 15% (p<0.01) compared to baseline, indicating a slowing of gastric rhythm. Furthermore, the regularity index of gastric electrical activity significantly increased by 22% (p<0.005), suggesting a more organized and less erratic pattern of electrical signals. These changes were strongly correlated with the observed clinical outcomes. > The most significant finding was a 2.5-fold increase in the power of postprandial gastric slow waves, which directly correlated with a 10.3% average reduction in body weight and improved satiety scores (p<0.001). This suggests Semaglutide not only slows gastric rhythm but also enhances the efficiency of gastric contractions.
Why It Matters
This study provides novel mechanistic insights into how Semaglutide exerts its therapeutic effects beyond simply delaying gastric emptying. Understanding these specific changes in gastric electrical activity could optimize treatment strategies and potentially lead to the development of more targeted therapies for obesity and gastric motility disorders. These findings pave the way for future larger clinical trials to confirm these mechanisms and explore their predictive value for patient response. Further research could investigate if specific gastric electrical patterns predict better weight loss outcomes.